Clinical Trial Update: Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial update on Infigratinib for FGFR-mutant advanced or metastatic solid tumors, including cholangiocarcinoma. Results posted 2025-06-10.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Infigratinib (BGJ398) (infigratinib)

Snippet

Sponsor: Sameek Roychowdhury | Conditions: Advanced Malignant Solid Neoplasm, Cholangiocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-06-10